Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
about
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection.Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitopeDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityConcatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesBovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific AntibodiesCapsomer vaccines protect mice from vaginal challenge with human papillomavirusPapillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodiesThe papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domainsCommon neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidationPositively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response.Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsidIn vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.Study of infectious virus production from HPV18/16 capsid chimeras.Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunityMultivalent human papillomavirus l1 DNA vaccination utilizing electroporation.Cell surface-binding motifs of L2 that facilitate papillomavirus infection.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.Antibody-mediated neutralization of flaviviruses: a reductionist view.High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.Immunoprevention of human papillomavirus-associated malignanciesA serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells.Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.How will HPV vaccines affect cervical cancer?Papillomavirus capsid binding and uptake by cells from different tissues and species.Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells.Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptorHuman papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments.Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
P2860
Q24524176-4CAC23C1-BF94-45C9-8531-FE6A8E65A333Q24796150-814BD686-620C-4C08-9E28-F49FCA58E208Q27654848-16D9D3D9-444A-4607-934E-098900FD3D88Q28246307-6A37CE32-8F3E-4F72-BDAF-91AF3F7890E1Q28593400-B3349546-22C6-4D35-8EB4-28A46226FE2CQ28611356-8A387B08-08B8-4494-8F9F-C48B259F81CAQ28743261-251F2543-164E-4FCD-9D50-F292DBD91D02Q33780651-06EBB46B-7AE2-4F15-B140-29A9002A3D9BQ33781905-557E33A4-E846-4886-8EF1-065BC8DF31E5Q33816200-94FCEB9A-C6BC-4A4C-9B6F-3DB3509D610DQ33839721-3B6FED4C-1916-463A-BC11-AE7743056967Q33848323-744A7374-1512-4DFC-A7DB-F8DE29147393Q33850734-469F9022-3DA6-4093-AE91-24170C2313E7Q33950282-D7AF23A5-1266-4FDB-BBF4-70BD0AC82CEFQ33953046-5552CA74-1F5A-4BC6-9DC8-4CF995C0026AQ34036827-948E674D-5A68-414D-885D-39836947AC97Q34069054-47B5BEF5-84A3-4170-B61E-ADB1AF66A39DQ34071813-B9D5AAE8-AD5D-4E79-99C6-DB63C0DA4BC7Q34227402-B51C17DB-707C-4877-8C01-D35997A92C75Q34347179-6744813E-B410-4E87-873A-7436EB55CB5FQ34352416-CE27E6A2-8F15-4F04-9B2E-817AD48AF981Q34639978-59F7B905-74E8-4A50-B826-D84E40CEA829Q34743921-5716506F-53E8-47CD-BC1F-71614746C557Q34786808-E27DFC61-2E0B-406C-81F1-F41D46879051Q34999617-9ED643BC-8C1E-40EF-AB77-CBFD97A9E65EQ35016793-196DA5E1-EE16-4E5E-BF9D-33358BDABDB6Q35044376-CEE4E804-F785-4E0C-A40C-4CB997290BA5Q35053221-3546B67D-DC42-4386-8794-AD24CB6434F7Q35076730-88C44F81-705F-40FE-A8E6-CAEEF1E5D52FQ35088658-DE27B8F0-6F37-48DF-8B4B-C6C62DF7DD11Q35235035-D6A319D2-AC35-4F56-8D90-52E3DE965DA4Q35831992-6356865B-74C9-4ED0-B8B4-3E41F9E9B230Q35839345-7DC92E9E-745A-4A09-8A05-6EFA197DD9A3Q35845291-5E4EEF39-8AA9-4A05-AFDA-4748B515386AQ35852125-CB8950E6-62DC-436C-A51E-50EBD0EA4104Q35854601-D17F40D4-78C6-4AAF-8CAD-8B422E7B88A7Q35860748-1A672BA2-9A53-4D21-B4A7-FE71887DF904Q35867810-C8FB4D82-F566-422A-BF0F-B184D9FE2DACQ35890718-D77CD49D-1BF8-4253-88EF-B7371AF665CDQ35891225-D2BF5551-5605-4C64-91F2-971113FF0E61
P2860
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
@ast
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
@en
type
label
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
@ast
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
@en
prefLabel
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
@ast
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
@en
P2093
P2860
P1433
P1476
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins
@en
P2093
Henderson DW
Kirnbauer R
Mushinski JF
Schiller JT
Weissinger EM
P2860
P304
P407
P577
1994-11-01T00:00:00Z